193 related articles for article (PubMed ID: 27064522)
1. FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.
Pietilä M; Vijay GV; Soundararajan R; Yu X; Symmans WF; Sphyris N; Mani SA
Sci Rep; 2016 Apr; 6():23070. PubMed ID: 27064522
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1-mediated phosphorylation of Forkhead box protein M1b antagonizes its SUMOylation and facilitates its mitotic function.
Zhang J; Yuan C; Wu J; Elsayed Z; Fu Z
J Biol Chem; 2015 Feb; 290(6):3708-19. PubMed ID: 25533473
[TBL] [Abstract][Full Text] [Related]
3. Involvement of Polo-like kinase 1 (Plk1) in quiescence regulation of cancer stem-like cells of the gastric cancer cell lines.
Zhu L; Xing S; Zhang L; Yu JM; Lin C; Yang WJ
Oncotarget; 2017 Jun; 8(23):37633-37645. PubMed ID: 28430578
[TBL] [Abstract][Full Text] [Related]
4. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression.
Fu Z; Malureanu L; Huang J; Wang W; Li H; van Deursen JM; Tindall DJ; Chen J
Nat Cell Biol; 2008 Sep; 10(9):1076-82. PubMed ID: 19160488
[TBL] [Abstract][Full Text] [Related]
5. JNK-associated Leucine Zipper Protein Functions as a Docking Platform for Polo-like Kinase 1 and Regulation of the Associating Transcription Factor Forkhead Box Protein K1.
Ramkumar P; Lee CM; Moradian A; Sweredoski MJ; Hess S; Sharrocks AD; Haines DS; Reddy EP
J Biol Chem; 2015 Dec; 290(49):29617-28. PubMed ID: 26468278
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of PLK1 inhibition in triple-negative breast cancer.
Ueda A; Oikawa K; Fujita K; Ishikawa A; Sato E; Ishikawa T; Kuroda M; Kanekura K
Lab Invest; 2019 Sep; 99(9):1275-1286. PubMed ID: 30996295
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
[TBL] [Abstract][Full Text] [Related]
8. The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation.
Yuan C; Wang L; Zhou L; Fu Z
Cell Cycle; 2014; 13(5):807-19. PubMed ID: 24407358
[TBL] [Abstract][Full Text] [Related]
9. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.
Hollier BG; Tinnirello AA; Werden SJ; Evans KW; Taube JH; Sarkar TR; Sphyris N; Shariati M; Kumar SV; Battula VL; Herschkowitz JI; Guerra R; Chang JT; Miura N; Rosen JM; Mani SA
Cancer Res; 2013 Mar; 73(6):1981-92. PubMed ID: 23378344
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1: target and regulator of transcriptional control.
Martin BT; Strebhardt K
Cell Cycle; 2006 Dec; 5(24):2881-5. PubMed ID: 17172872
[TBL] [Abstract][Full Text] [Related]
11. PLK1 Activation in Late G2 Sets Up Commitment to Mitosis.
Gheghiani L; Loew D; Lombard B; Mansfeld J; Gavet O
Cell Rep; 2017 Jun; 19(10):2060-2073. PubMed ID: 28591578
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas.
Dibb M; Han N; Choudhury J; Hayes S; Valentine H; West C; Sharrocks AD; Ang YS
BMC Res Notes; 2015 Nov; 8():676. PubMed ID: 26576650
[TBL] [Abstract][Full Text] [Related]
13. Human mitochondrial Fis1 links to cell cycle regulators at G2/M transition.
Lee S; Park YY; Kim SH; Nguyen OT; Yoo YS; Chan GK; Sun X; Cho H
Cell Mol Life Sci; 2014 Feb; 71(4):711-25. PubMed ID: 23907611
[TBL] [Abstract][Full Text] [Related]
14. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
[TBL] [Abstract][Full Text] [Related]
15. WAC Promotes Polo-like Kinase 1 Activation for Timely Mitotic Entry.
Qi F; Chen Q; Chen H; Yan H; Chen B; Xiang X; Liang C; Yi Q; Zhang M; Cheng H; Zhang Z; Huang J; Wang F
Cell Rep; 2018 Jul; 24(3):546-556. PubMed ID: 30021153
[TBL] [Abstract][Full Text] [Related]
16. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
17. The Catalytic Subunit of DNA-Dependent Protein Kinase Coordinates with Polo-Like Kinase 1 to Facilitate Mitotic Entry.
Lee KJ; Shang ZF; Lin YF; Sun J; Morotomi-Yano K; Saha D; Chen BP
Neoplasia; 2015 Apr; 17(4):329-38. PubMed ID: 25925375
[TBL] [Abstract][Full Text] [Related]
18. P21-activated kinase is required for mitotic progression and regulates Plk1.
Maroto B; Ye MB; von Lohneysen K; Schnelzer A; Knaus UG
Oncogene; 2008 Aug; 27(36):4900-8. PubMed ID: 18427546
[TBL] [Abstract][Full Text] [Related]
19. A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells.
Patel JR; Thangavelu P; Terrell RM; Israel B; Sarkar AB; Davidson AM; Zhang K; Khupse R; Tilghman SL
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454120
[TBL] [Abstract][Full Text] [Related]
20. G
Giráldez S; Galindo-Moreno M; Limón-Mortés MC; Rivas AC; Herrero-Ruiz J; Mora-Santos M; Sáez C; Japón MÁ; Tortolero M; Romero F
FASEB J; 2017 Jul; 31(7):2925-2936. PubMed ID: 28360195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
